My reference point on pricing
I was early on a stock called LOXO. They made a successful drug for sold tumours with a very specific genetic mutation. Not as big a target market as TLT would aim for one day with IV Rutherrin.
LOXO was bought out for 6B usd (Bayer).
If TLT ever reached that (who knows....) that would mean a share price closer to 20 USD.
Nice to dream sometimes.